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Abstract: Purpose: Women whose mammographic breast density declines within 12–18 months
of initiating tamoxifen for chemoprevention or adjuvant treatment show improved therapeutic
responses compared with those whose density is unchanged. We tested whether measuring changes
in sound speed (a surrogate of breast density) using ultrasound tomography (UST) could enable rapid
identification of favorable responses to tamoxifen. Methods: We evaluated serial density measures
at baseline and at 1 to 3, 4 to 6, and 12+ months among 74 women (aged 30–70 years) following
initiation of tamoxifen for clinical indications, including an elevated risk of breast cancer (20%) and
diagnoses of in situ (39%) or invasive (40%) breast carcinoma, enrolled at Karmanos Cancer Institute
and Henry Ford Health System (Detroit, MI, USA). For comparison, we evaluated an untreated
group with screen negative mammography and frequency-matched on age, race, and menopausal
status (n = 150), at baseline and 12 months. Paired t-tests were used to assess differences in UST
sound speed over time and between tamoxifen-treated and untreated patients. Results: Sound
speed declined steadily over the 12 month period among patients receiving tamoxifen (mean (SD):
−3.0 (8.2) m/s; p = 0.001), whereas density remained unchanged in the untreated group (mean
(SD): 0.4 (7.1) m/s; p = 0.75 (relative change between groups: p = 0.0009)). In the tamoxifen group,
we observed significant sound speed reductions as early as 4–6 months after tamoxifen initiation
(mean (SD): −2.1 (6.8) m/s; p = 0.008). Sound speed reductions were greatest among premenopausal
patients (P-interaction = 0.0002) and those in the middle and upper tertiles of baseline sound speed
(P-interaction = 0.002). Conclusions: UST can image rapid declines in sound speed following initiation
of tamoxifen. Given that sound speed and mammographic density are correlated, we propose that
UST breast imaging may capture early responses to tamoxifen, which in turn may have utility in
predicting therapeutic efficacy.
Keywords: breast density; breast neoplasms; tamoxifen; ultrasonography; tomography; chemoprevention
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1. Introduction
Tamoxifen is a selective estrogen receptor modulator which reduces risk of estrogen
receptor (ER)-positive breast cancer risk by 50% in the prevention setting for women at
high breast cancer risk (e.g., based on the Gail model) [1] and lowers mortality by 30%
in the adjuvant setting irrespective of grade [2]. Elevated mammographic breast density
is one of the strongest risk factors for breast cancer in the general population [3], and
studies suggest that declines in density with tamoxifen use may represent a marker of
efficacy in both prevention and treatment [4–7]. However, imprecision in measurement
of mammographic density renders detection of small changes in density difficult, and
serial assessment is limited by repeated radiation exposure. Furthermore, limitations of
mammography include the need for breast compression, which distorts architecture and
varies between examinations, and which may limit the reproducibility of two-dimensional
measurements of breast density.
To assess breast density repeatedly over time while avoiding ionizing radiation, we
used a novel ultrasound tomography (UST) scanner to measure volumetric breast density
without compression in women before and during their first year of tamoxifen use for
clinical indications, including chemoprevention and treatment. UST examination calculates
sound speed within the breast, an objective physical measurement that is directly related
to tissue density [8–12]. As units of sound speed are fixed to an external standard, UST
breast sound speed measurements are relatively unaffected by day-to-day performance
factors [13]. UST whole-breast sound speed estimates have been previously shown to
be highly reproducible surrogate measures of volumetric breast density [14–19], which
are strongly and positively associated with breast cancer risk [17]. The specific goal of
this project was to utilize UST to describe the early time course of tamoxifen-associated
volumetric breast density declines. The broader objective was to assess the concept of
breast density decline as a biosensor of tamoxifen response and UST as a useful tool for
making this determination. For comparison, we assessed a group of matched untreated
women with screen negative mammography at a 12 month interval.
2. Materials and Methods
2.1. Study Population
The Ultrasound Study of Tamoxifen enrolled 82 patients referred for tamoxifen therapy
for clinical indications and a matched comparison group of 165 untreated women with
screen negative mammograms and no personal history of breast cancer, aged 30–70 years, at
the Barbara Ann Karmanos Cancer Institute (KCI) and Henry Ford Health System (HFHS)
in Detroit, MI, USA from 2011 to 2014 [13,17]. Patients were ineligible for study enrollment
if they were pregnant, were lactating, had active skin infections or open chest wounds,
had a breast size more than 22 cm in diameter (limit of the size of the ring ultrasound
transducer), or weighed over 350 lb (weight limit, as specified by the manufacturer of
the UST table). Furthermore, ineligible patients included those with breast implants or
reduction mammoplasty or who were taking endogenous hormones at the time of study
enrollment (i.e., oral contraceptives and menopausal hormone therapy), because the use
and discontinuation of these medications may alter breast density [20].
For the tamoxifen-treated group, patients were identified at KCI and HFHS prior
to tamoxifen initiation from a health professional’s referral based on their elevated risk
of breast cancer, including a diagnosis of atypical lobular or atypical ductal hyperplasia
(ALH/ADH), ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or unilateral
invasive breast cancer. Women with a prior cancer diagnosis in the breast contralateral
to their diagnosis at the time of study referral were ineligible; similarly, women with a
diagnosis of bilateral synchronous breast cancer were ineligible for the tamoxifen group, as a
breast without cancer would not have been available for analysis. In order to assess whether
any observed changes in UST density over time were greater than the minimal declines
in breast density that might be observed with aging in the absence of tamoxifen exposure,
we identified an untreated group from patients undergoing screening mammography at

J. Clin. Med. 2022, 11, 792

3 of 12

KCI or HFHS with the recommendation to continue routine screening (i.e., Breast Imaging
Reporting and Data System (or BI-RADS) diagnostic score of “1” or “2”). In addition,
these women had not received medication or radiation for cancer and were not taking
tamoxifen or raloxifene to lower breast cancer risk. Untreated women were invited to
undergo UST and were frequency-matched to the case group on the basis of age (within
1 year categories where possible), race, and menopausal status. A previous analysis in this
study population compared baseline measures of breast sound speed and mammographic
breast density in tamoxifen-treated and untreated patients, with findings demonstrating
that baseline measures of UST sound speed were more strongly associated with breast
cancer risk than mammographic breast density [17]. The focus of the present analysis was
to assess differences in UST sound speed over time and between tamoxifen-treated and
untreated patients.
For the purposes of this analysis, n = 6 women in the group recommended to receive
tamoxifen who did not initiate therapy were excluded. In addition, the analysis was
restricted to the ~90% of participants who completed the baseline UST scan and at least
one follow-up UST scan, resulting in a final analytic population of n = 74 in the tamoxifen
group and n = 150 in the untreated group (Figure S1). Informed consent was obtained from
all participants, and the study protocol was approved by the Institutional Review Boards
at KCI, HFHS, and the NCI.
2.2. Breast Sound Speed Assessment
Among the tamoxifen-treated patients, a baseline UST scan was completed prior to
tamoxifen initiation (T0) and at approximately 1–3 months (T1), 4–6 months (T2), and
12 months (T3) post tamoxifen initiation (Figure 1). Among those breast cancer patients
diagnosed with high-risk breast lesions or cancer, UST was completed for the contralateral
breast to avoid the potential influences of biopsy changes on breast sound speed. For
breast cancer patients receiving neoadjuvant chemotherapy prior to initiating tamoxifen
therapy (n = 7), the sequence of the four UST scans was modified in an attempt to isolate
the influence of tamoxifen on breast UST sound speed as follows: prior to treatment,
post chemotherapy and prior to tamoxifen (defined as T0 for the purposes of the present
analysis), and at approximately 1–3 months (T1) and 12 months (T3) post tamoxifen
initiation. The untreated group underwent two UST scans, at baseline and at a 12 month
follow-up visit. For this group, we randomly selected a breast for UST assessment and
imaged the same breast at baseline and follow-up, since concurrent mammographic density
measurements of left and right breasts from the same individuals have been reported to be
highly correlated [21].
UST scans were performed at KCI with the SoftVue system, a clinical prototype
manufactured by Delphinus Medical Technologies (Novi, MI, USA), cleared by the FDA
for clinical use, and recently approved for breast cancer screening [13,17,19]. Patients were
scanned in the prone position with the breast immersed in a water bath. UST uses a 22 cm
ring-shaped ultrasound transducer, consisting of 2048 elements that transmit and receive
ultrasound pulses. The transducer is mounted on an automated gantry that progressively
captures 40–100 coronal image slices beginning at the chest wall and progressing to the
nipple, requiring about 90 s to capture the raw data. Images were reconstructed from the
raw data and output in DICOM format. The volume averaged sound speed (VASS, m/s) of
the breast, a surrogate of volumetric breast density [14–19], was calculated using techniques
described previously [8,13,17]. Briefly, to minimize background noise, a segmentation
algorithm was utilized to remove sections of each image associated with the water bath.
To analyze change in sound speed between serial scans, image files were restricted to
a common volume that was contained within all scans [13]. For tomograms included
in the common volume, the sound speed measures, in m/s, were calculated through a
direct count of pixel values in each tomogram using automated scripts and were averaged
together for the image stack to generate the VASS measurement used as a proxy of breast
density. Observers were blinded to tamoxifen status for UST sound speed measurements. A
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previous reproducibility study demonstrated that UST VASS estimates were highly reliable
for a single timepoint (intraclass correlation coefficient, ICC = 93.4%) and had very good
reproducibility for changes in VASS (ICC = 70.4%) [13].

Figure 1. Assessing interval changes in volumetric breast density with ultrasound tomography in
the Ultrasound Study of Tamoxifen. Purple = tamoxifen-treated group (N = 74); maroon = untreated
group (N = 150).

2.3. Covariates
At the time of each UST scan, a standard health history questionnaire was administered
by a research nurse to collect demographics, reproductive history, menopausal status, and
medication use. Measured height was collected at baseline and measured weight was
collected at each UST scan to compute body mass index (BMI, kg/m2 ) and to evaluate
change in BMI over time.
2.4. Statistical Analysis
Participant characteristics between the tamoxifen-treated and untreated groups were
compared using chi-square or Fisher’s exact tests for categorical variables and the Wilcoxon
rank sum test for continuous variables. Mean change in VASS from baseline to follow-up
was approximately normally distributed in both groups. We evaluated mean change in
VASS by participant characteristics using paired t-tests or Kruskal–Wallis tests as appropriate. In sensitivity analyses, we adjusted for weight change at 12 months (tertiles) using
generalized linear regression models. Changes in VASS measures over time were evaluated
separately among cases and controls using paired t-tests. To compare the average change
in VASS over the 12 month follow-up period between cases and controls, a two-sample
t-test was used.
Relative change in VASS in the tamoxifen-treated versus untreated groups was assessed with generalized linear regression models that accounted for repeated measures
from the same woman in the variance calculation [22]. The models included time since
tamoxifen initiation (in months) and the matching factors; we additionally tested for effect
modification of this relationship by menopausal status and baseline VASS. Sensitivity
analyses were conducted excluding breast cancer patients who underwent neoadjuvant
chemotherapy, who became postmenopausal by 12 month visit, or who self-reported tamoxifen cessation at any visit over study follow-up. Analyses were performed using SAS
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V9.4 (SAS, Cary, NC, USA). We compared regression coefficients for time from the separate
GLM models using chi-squared tests to obtain p-values for interaction (test statistics were
calculated in R). Statistical tests were two-sided, and p-values < 0.05 were considered
statistically significant.
3. Results
Of the 74 tamoxifen-treated patients, 96% completed the T1 scan (1–3 months post
tamoxifen initiation), 89% completed the T2 scan (4–6 months post tamoxifen initiation) and
95% completed the T3 scan (12 months post tamoxifen initiation). Indications for tamoxifen
were as follows: 15 (20%) were high-risk patients (i.e., without histologically confirmed
in situ or invasive breast cancer), 29 (39%) were diagnosed with in situ carcinoma, and
30 (40%) were diagnosed with invasive breast cancer, including n = 7 who were prescribed
neoadjuvant chemotherapy. Furthermore, n = 2 tamoxifen-treated patients (3%) reported
stopping tamoxifen prior to T2, and n = 4 tamoxifen-treated patients (6%) reported stopping
tamoxifen prior to T3.
Participant characteristics are shown in Table 1. No statistically significant differences
were observed between groups in matching factors (i.e., age, race and menopausal status).
Median (range) age at baseline was 51 (30–70) years among tamoxifen-treated patients and
51 (33–69) among untreated patients. Slightly over 50% of women in both groups were
Black and premenopausal and over 75% were overweight or obese. Weight change was
minimal over the study period in both groups. Compared with untreated women, patients
receiving tamoxifen were more likely to have a first degree relative with breast cancer (32%
vs. 20%; p = 0.04) and to have elevated baseline VASS (p = 0.01), as previously reported in
this study population [17].
Table 1. Characteristics of tamoxifen-treated and untreated patients without a personal history of
breast cancer, in the Ultrasound Study of Tamoxifen.
Tamoxifen-Treated Group (N = 74)
Characteristic
Age at baseline—Median (Range)
Age at baseline
<45
45–50
50–55
≥55
Race
White
Black
Other
Hispanic
No
Yes
BMI at baseline
<25
25–30
30+
BMI at 12 month follow-up
<25
25−30
30+
Weight change (lbs)—median (IQR)
Weight change at 12 months (lbs)
<−2.4
−2.4–3.4
≥3.4

Untreated Group (N = 150)

p-Value *

N

%

N

%

51.3

(30, 71)

51.1

(33, 69)

0.68 **

17
17
17
23

23.0
23.0
23.0
31.1

32
36
32
50

21.3
24.0
21.3
33.3

0.97

26
41
7

35.1
55.4
9.5

46
99
5

30.7
66.0
3.3

0.10

70
4

94.6
5.4

146
4

97.3
2.7

0.44 †

16
24
34

21.6
32.4
45.9

32
42
76

21.3
28.0
50.7

0.76

17
24
29
1

24.3
34.3
41.4
(−4.2, 5.7)

33
39
78
−0.1

22.0
26.0
52.0
(−4.6, 4.8)

0.31

26
15
29

37.1
21.4
41.4

51
51
48

34.0
34.0
32.0

0.15

0.51
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Table 1. Cont.
Tamoxifen-Treated Group (N = 74)
Characteristic
Education
At most, high school/GED
Some college/postsecondary courses
College/graduate school
Age at menarche
≤12
13
14+
Age at first birth
Nulliparous
<18
18–21
22–27
27+
Menopausal status
Premenopausal
Postmenopausal
Any first-degree relative with breast
cancer
No
Yes
Quartiles of baseline sound speed (m/s)
<1440.63
1440.63–1445.65
1445.65–1452.81
≥1452.81

Untreated Group (N = 150)

p-Value *

N

%

N

%

23
24
27

31.1
32.4
36.5

43
51
56

28.7
34.0
37.3

0.93

41
14
19

55.4
18.9
25.7

86
35
28

57.7
23.5
18.8

0.44

11
7
13
17
26

14.9
9.5
17.6
23.0
35.1

35
25
27
32
31

23.3
16.7
18.0
21.3
20.7

0.10

49
25

66.2
33.8

84
66

56.0
44.0

0.14

50
24

67.6
32.4

120
30

80.0
20.0

0.04

7
17
20
30

9.5
23.0
27.0
40.5

39
39
35
37

26.0
26.0
23.3
24.7

0.01

p-values < 0.05 are in bold font. * p-Values from chi-square test except where noted; ** p-values from Wilcoxon rank
sum test; † p-values from Fisher’s exact test. BMI, body mass index; IQR, interquartile range; MHT, menopausal
hormone therapy.

The median (range) time between the baseline UST scan (T0) and the follow-up UST
scan (T3) was 13 (7–21) months in the treated and 13 (10–26) months in the untreated
groups. Associations between participant characteristics and change in VASS from baseline
(T0) to the T3 follow-up scan are presented in Table 2. In both groups, weight gain
at T3 was associated with a statistically significant reduction in VASS at T3 (p ≤ 0.02).
Among tamoxifen-treated women, premenopausal status at baseline was associated with
a statistically significant reduction in VASS at T3 (mean (SD): −4.2 (9.0) m/s; p = 0.02).
On average, greater decreases in VASS from baseline to T3 were observed for patients
with higher baseline VASS in both treated (p = 0.0001) and untreated women (p = 0.04).
Observed risk factor relationships were attenuated slightly with adjustment for weight
change between T0 and T3 (Table 2).
Table 2. Mean change in sound speed (m/s) from baseline to 12 month follow-up in the tamoxifentreated and untreated groups by participant characteristics, in the Ultrasound Study of Tamoxifen.
Tamoxifen-Treated Group (N = 74)
Characteristic

Mean (SD)

p-Value *

Age at baseline
<45
45–50
50–55
≥55

−1.9 (10.9)
−4.7 (7.6)
−3.9 (8.4)
−1.8 (6.2)

0.51

p-Value
0.58

Untreated Group (N = 150)
†

Mean (SD)

p-Value *

p-Value †

0.5 (6.2)
0.8 (7.9)
−0.6 (9.0)
0.7 (5.7)

0.66

0.64
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Table 2. Cont.
Tamoxifen-Treated Group (N = 74)
Characteristic
Race
White
Black
Other
Hispanic
No
Yes
BMI at baseline
<25
25–30
30+
BMI at 12 month follow-up
<25
25–30
30+
Weight change at 12 months (lbs)
<−2.4
−2.4–3.4
≥3.4
Education
At most, high school/GED
Some college/postsecondary courses
College/graduate school
Age at menarche
≤12
13
14+
Age at first birth
Nulliparous
<18
18–21
22–27
27+
Menopausal status
Premenopausal
Postmenopausal
Any first degree relative with breast
cancer
No
Yes
Quartiles of baseline sound speed (m/s)
<1440.63
1440.63–1445.65
1445.65–1452.81
≥1452.81

Untreated Group (N = 150)

Mean (SD)

p-Value *

p-Value †

Mean (SD)

p-Value *

p-Value †

−4.0 (8.9)
−2.5 (8.0)
−2.4 (7.3)

0.99

0.73

1.0 (5.7)
0.0 (7.7)
2.1 (4.6)

0.83

0.38

−3.2 (8.2)
0.7 (7.6)

0.79 **

0.28

0.4 (7.2)
1.5 (2.7)

0.62 **

0.41

−6.7 (9.8)
−2.1 (6.7)
−2.1 (8.2)

0.42

0.31

−0.1 (8.8)
−0.6 (8.9)
1.1 (4.8)

0.40

0.34

−4.4 (10.0)
−3.1 (6.3)
−2.1 (8.5)

0.89

0.50

0.7 (9.3)
0.3 (8.7)
0.3 (4.9)

0.89

0.68

0.2 (7.9)
−2.5 (8.1)
−6.2 (7.5)

0.02

–

2.0 (8.3)
1.2 (5.7)
−2.2 (6.5)

0.0004

–

−2.4 (7.2)
−2.0 (9.1)
−4.3 (8.4)

0.79

0.77

−0.4 (8.9)
−0.0 (7.0)
1.4 (5.4)

0.53

0.46

−2.9 (9.1)
−0.5 (5.2)
−5.0 (7.5)

0.25

0.32

0.6 (7.3)
1.1 (5.4)
−1.1 (8.2)

0.63

0.49

−4.1 (8.1)
−2.4 (2.9)
0.3 (7.3)
−3.4 (5.9)
−4.1 (10.5)

0.40

0.64

0.4 (8.7)
0.4 (9.5)
1.0 (4.6)
−0.5 (5.8)
0.8 (6.0)

0.89

0.8

−4.2 (9.0)
−0.6 (5.5)

0.02 **

0.09

0.5 (6.7)
0.2 (7.5)

0.60 **

0.48

−3.0 (8.3)
−3.0 (8.1)

0.49 **

0.81

0.2 (7.0)
1.3 (7.6)

0.23 **

0.40

2.1 (3.3)
0.9 (3.6)
−2.1 (5.2)
−7.2 (10.4)

0.0001

0.013

2.3 (3.2)
1.7 (5.1)
−1.1 (6.3)
−1.5 (11.0)

0.04

0.06

* p-Values from Kruskal–Wallis test except where noted; p-values less than 0.05 are in bold font; ** p-values
from paired t-test; † p-values from generalized linear regression modeling after adjusting for weight change at
12 months (tertiles); p-values less than 0.05 are in bold font. BMI, body mass index; MHT, menopausal hormone
therapy; SD, standard deviation.

At the T3 scan, VASS was statistically significantly reduced in the tamoxifen-treated
group (mean (SD): −3.0 (8.2) m/s; p = 0.0015), while VASS remained stable in the untreated
group (mean (SD): 0.4 (7.1) m/s; p = 0.75) (Figure 2). The difference in density change
between groups was statistically significant (p = 0.0009).
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Figure 2. Mean (SE) reductions in breast volume average sound speed between baseline and
12 months by tamoxifen-treated (N = 74) and untreated (N = 150) study groups, in the Ultrasound
Study of Tamoxifen.

In analyses restricted to the tamoxifen-treated group, we observed significant reductions in VASS as early as 4–6 months after initiation of drug (Figure 3, mean (SD):
−2.1 (6.8) m/s; p = 0.008). Results from linear regression models adjusted for matching
factors indicated that, for every month post tamoxifen initiation, VASS decreased by −0.31
m/s (95% confidence interval (CI): −0.47, −0.14; p = 0.0004). Example UST sound speed
images from a tamoxifen-treated premenopausal patient are shown in Figure 4. VASS
reductions were greatest among premenopausal tamoxifen-treated women (Figure S2,
P-interaction = 0.0002) and those in the middle and upper tertiles of baseline VASS (Pinteraction = 0.002). Results from sensitivity analyses excluding seven tamoxifen-treated patients who underwent neoadjuvant chemotherapy, four premenopausal tamoxifen-treated
patients who underwent menopause by the end of study follow-up, and four tamoxifentreated patients who self-reported cessation of tamoxifen over the study follow-up period
were consistent with the overall study results.

Figure 3. Mean (SE) reductions in breast volume average sound speed by study visit in the tamoxifentreated group (N = 74), in the Ultrasound Study of Tamoxifen.
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Figure 4. Example of single ultrasound tomography sound speed images from the breast contralateral
to a diagnosis of invasive breast cancer in a tamoxifen-treated premenopausal patient over the course
of the study follow-up period. Dense tissue appears white on the image with higher sound speed
values, while fatty tissue appears dark with lower sound speed values. Among the tamoxifen-treated
group, we observed significant VASS declines as early as 4–6 months post tamoxifen initiation (T2),
with the strongest results observed among premenopausal patients.

4. Discussion
Using novel nonionizing whole-breast UST to repeatedly assess VASS, a reliable and
accurate surrogate of volumetric breast density, we found that VASS decreased steadily and
rapidly within the first year of tamoxifen therapy, while remaining stable in an untreated
matched comparison group. Furthermore, we observed significant VASS declines as early
as 4–6 months post tamoxifen initiation, with strongest results among premenopausal
patients. These findings suggest that UST may have utility in monitoring early changes in
VASS as a potential biomarker of clinical tamoxifen response. Further studies are needed
to assess underlying mechanisms and to determine whether this observation can predict
clinical outcome, as has been shown for decline in mammographic density.
Our UST findings are consistent with prior studies demonstrating that tamoxifen can
induce decreases in mammographic breast density in both high-risk women and breast
cancer patients [4]. Previous studies have shown that women whose mammographic
breast density declines 12–18 months after receiving tamoxifen for chemoprevention or
adjuvant treatment are more likely to gain benefit than those whose breast density does
not decline [5–7]. In the IBIS-1 chemoprevention trial of tamoxifen vs. placebo, women
in the tamoxifen arm experienced a significantly greater decline in density as compared
with placebo at 5 years (13.7% vs. 7.3%, respectively; p < 0.001). About two-thirds of the
reduction in density attained with tamoxifen occurred within 18 months (7.9% vs. 3.5%,
p < 0.001) [23]. Subsequent data from IBIS-1 indicated that successful chemoprevention
with tamoxifen use was strongly related to a decline in mammographic density by ~10% or
more at 12–18 months [24]. Mammographic density decline 12–18 months post tamoxifen
initiation has also been linked to reductions in breast cancer recurrence and improved
breast cancer-specific survival [5–7].
We observed a statistically significant reduction in VASS as early as 4–6 months post
tamoxifen initiation. Given that screening was performed annually in IBIS-1, the trial was
unable to assess whether density declines associated with tamoxifen use occurred earlier
than 1 year, and most prior studies evaluated density change at yearly intervals [5–7].
Consistent with our findings, however, a recent report from a 6 month low-dose tamoxifen
trial from the Swedish KARMA Cohort identified significant reductions in mammographic
breast density with both 2.5 and 20 mg doses of tamoxifen, primarily in premenopausal
women [25]. Future work is needed to determine whether low-dose tamoxifen, which
confers fewer side-effects than the standard 20 mg dose [26], in concert with early tamoxifenassociated declines in breast density, may predict therapeutic effectiveness. UST may be a
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valuable low-risk and reliable tool for rapidly determining which patients are responding
to therapy, which would have important clinical implications as tamoxifen uptake and
adherence remain low due to concerns about toxicities and vasomotor symptoms [27].
Furthermore, defining a biomarker of effectiveness could potentially suggest a path to
precision dosing and reducing side-effects.
It is unclear why tamoxifen-associated density declines appear to be greater in premenopausal as compared with postmenopausal women, despite the beneficial chemopreventive and adjuvant effects of tamoxifen therapy irrespective of menopausal status [2,28].
As postmenopausal women tended to have lower baseline breast density as compared with
premenopausal women, there was a smaller range of densities available post menopause in
which to measure declines. It has been hypothesized that breast density decline represents
a biosensor of tamoxifen response, reflecting estrogen suppression and the bioavailability
and action of active drug metabolites [5,29]. Future studies of serial circulating and tissuebased markers collected pre and post tamoxifen may provide mechanistic insights into the
biologic underpinnings of tamoxifen-associated density declines and related reductions in
breast cancer risk and progression.
Strengths of this study include the longitudinal study design with the use of a novel
3D UST imaging device to repeatedly assess VASS, a previously defined surrogate of
breast density [14–18], in well-characterized tamoxifen-treated and untreated matched
comparison groups. UST is well suited for this application because it produces volumetric
data and avoids artefacts secondary to breast compression and exposure to potentially
harmful ionizing radiation. As VASS is an objective physical measurement that is fixed
to an external standard, UST VASS is relatively unaffected by day-to-day performance
factors and has demonstrated reliability for measuring density change [13]. Furthermore,
in this study population, risk factors associated with density declines (e.g., premenopausal
status, elevated baseline density) were consistent with those reported in prior studies
using mammography to assess density change [23,25,30], lending validity to our findings.
Although limited in sample size, within-person comparisons reduced the potential for
confounding. Lastly, this was a short-term longitudinal study with change in VASS as
a biomarker endpoint. Prior studies have observed that mammographic breast density
measurements approximately 1 year after tamoxifen initiation are generally representative
of longer-term changes [31,32]. Future work is needed to evaluate the persistence of effects
of UST sound speed declines on breast cancer outcomes to establish VASS as a clinically
relevant biomarker.
In summary, we observed that UST measurement of VASS enables detection of rapid
declines after tamoxifen initiation, suggesting the potential to use VASS as an early
marker of tamoxifen response. Further studies are needed to assess whether patterns
of change in VASS over time among tamoxifen-treated patients can discriminate preventive
or adjuvant benefit.
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